Global brachytherapy devices market was valued at US $ 800 Mn in 2020 and expected to grow at 7.4% Compound Annual Growth Rate (CAGR) over 2021 to 2027. Brachytherapy is a type of radiotherapy that involves a procedure in which a radioactive material is placed inside the body giving a high radiation dose to the tumor while reducing the radiation exposure in the surrounding healthy tissues. Brachytherapy is commonly used as an effective treatment for cervical cancer, breast cancer, prostate cancer etc. Radiation therapy can be used as a preventative, palliative, or curative measure. It can also be used as a stand-alone treatment or in conjunction with other treatments such as surgery, immunotherapy, and chemotherapy. The wide range of applications for radiation has boosted its popularity among doctors. The most recent breakthroughs in radiation therapy allow for a high dose to be delivered to the target location while causing minimal damage to neighbouring healthy tissues. This has raised the possibilities of localised tumour control and improved cure rates, resulting in a surge in radiation therapy demand. However, a scarcity of experienced radiation specialists and technologically advanced goods, particularly in developing countries, is projected to be a major stumbling block for this industry. According to the IAEA’s Directory of Radiotherapy Centres (DIRAC), over 3300 brachytherapy systems will be installed in radiation therapy centres across the world by 2020. LMICs account for over 60% of cancer cases. Because these countries have restricted access to technologically advanced products, 80 percent of patients in these countries are unable to receive therapy. Only 3-4 percent of radiation demands in LMICs are addressed, compared to 60-80 percent in European countries for brachytherapy devices market.